Mostrar el registro sencillo del ítem

dc.contributor.author
Quinteros, Daniela Alejandra  
dc.contributor.author
Lopez, Emiliano Sebastian  
dc.contributor.author
Silva Couto, Juan Lucio  
dc.contributor.author
Maletto, Belkys Angélica  
dc.contributor.author
Allemandi, Daniel Alberto  
dc.contributor.author
Palma, Santiago Daniel  
dc.contributor.author
Gallo, Juan Eduardo Maria  
dc.date.available
2018-03-27T18:49:59Z  
dc.date.issued
2016-12  
dc.identifier.citation
Quinteros, Daniela Alejandra; Lopez, Emiliano Sebastian; Silva Couto, Juan Lucio; Maletto, Belkys Angélica; Allemandi, Daniel Alberto; et al.; Evaluation of the performance of an ophthalmic thermosensitive hydrogel containing combination of suramin and bevacizumab; Bentham Science Publishers; Current Pharmaceutical Design; 22; 43; 12-2016; 6587-6594  
dc.identifier.issn
1381-6128  
dc.identifier.uri
http://hdl.handle.net/11336/40192  
dc.description.abstract
Suramab (SUM) is a new pharmaceutical combination made up of suramine (SUR) and bevacizumab (BVM), which showed a high synergistic effect when administered jointly. As the pharmaceutical vehicle, poloxamer aqueous dispersions were used since this system is able to maintain their fluidity at low temperatures (<15�C) but which become gel in the corporal environment (>35�C). In the present study we aimed at evaluating the effect of Poloxamer to prolong the effect of SUM. These formulations were characterized using rheological, biopharmaceutical (drug release) and morphological (SEM) technique. Corneal NV was induced in Sprague Dawley rats Corneal. At 15 days of follow up animals were sacrificed and perfused with black drawing ink. Digital photographs were taken and the area of neovascularisation (ANV) was calculated using the image programmed. The rheological behavior was influenced by the addition of drugs, resulting in a decrease in the gelation temperature (Tsol/gel). Both drugs were released from poloxamer gels by means of an anomalous mechanism. However, BVM was released faster than SUR, with their combination (SUM) to appearing to reduce delivery, probably due to interactions between the drugs or with the polymeric matrix. The in vivo studies showed that SUM-poloxamer gel was able to increase the corneal antiangiogenic effect compared to the SUM solution and BVM alone at 15 days of follow-up. Furthermore no injurious effects were observed in the histological tissue examination after drug administration. The presence of Poloxamer, known to modulate control release of biological agents, seems to have a favorable effect on SUM subconjunctival administered.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Bentham Science Publishers  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Bevacizumab  
dc.subject
Controlled Release  
dc.subject
Neovascularization  
dc.subject
Poloxamer  
dc.subject
Suramab  
dc.subject
Suramine  
dc.subject
Thermosensitive Hydrogels  
dc.subject.classification
Farmacología y Farmacia  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.subject.classification
Farmacología y Farmacia  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Evaluation of the performance of an ophthalmic thermosensitive hydrogel containing combination of suramin and bevacizumab  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2018-03-27T15:17:01Z  
dc.journal.volume
22  
dc.journal.number
43  
dc.journal.pagination
6587-6594  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
Oak Park  
dc.description.fil
Fil: Quinteros, Daniela Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina  
dc.description.fil
Fil: Lopez, Emiliano Sebastian. Universidad Austral. Facultad de Ciencias Biomédicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Silva Couto, Juan Lucio. Universidad Austral. Facultad de Ciencias Biomédicas; Argentina  
dc.description.fil
Fil: Maletto, Belkys Angélica. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina  
dc.description.fil
Fil: Allemandi, Daniel Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina  
dc.description.fil
Fil: Palma, Santiago Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina  
dc.description.fil
Fil: Gallo, Juan Eduardo Maria. Universidad Austral. Facultad de Ciencias Biomédicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.journal.title
Current Pharmaceutical Design  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/144740/article  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.2174/1381612822666160811160832